On the heels of Takeda’s $300 million licensing deal for rusfertide, Protagonist Therapeutics’ peptide mimetic lowered hematocrit levels in patients with polycythemia vera, a type of blood cancer.
After treatment with a CD19 CAR-T therapy, patients with systemic lupus erythematosus, idiopathic inflammatory myositis or systemic sclerosis achieved long-lasting remission, according to results published in the NEJM.
According to Bavarian Nordic, its cancer vaccine TAEK-VAC has reached a stage where more investments are required. The company would also have faced stiff competition in the cancer vaccine space.
Despite this setback, AstraZeneca is looking to differentiate in the DKD space with its pipeline drug, zibotentan. If approved, having another treatment option could be of high value to physicians looking to find an optimal treatment of choice for individuals with DKD.
The progression-free survival metric has helped shepherd many products across the regulatory finish line. Experts say the FDA’s new emphasis on overall survival will be felt especially by small biotechs.
While the company did not provide specific reasons for the halt, Gilead Sciences said it is “reviewing the benefit-risk” of its anti-CD47 antibody magrolimab across all ongoing trials.
Kelonia Therapeutics’ in vivo gene placement system is being tapped to help Astellas Pharma expand its portfolio of in vivo CAR-T cell therapies for cancer.
Cancer testing biotech Freenome announced on Thursday that it has raised an additional $254 million in private financing to support the development of its multiomics-based early detection tests.
Roivant Sciences announced Tuesday during its third-quarter financial report that it will discontinue the development of its investigational SF3B1 modulator RVT-2001, following an interim analysis of a Phase I/II study in myelodysplastic syndromes.
Biogen misses Q4 revenue estimates on Aduhelm costs, lower MS drug sales Published: Feb 13, 2024 By Tyler Patchen BioSpace Biogen’s fourth-quarter financial results were weighed down by declining multiple […]
